Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0660

-1.5%

Dec 8 2:18 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	5/22/2013 8:09:43 AM
	Read Replies (1) of 13111

PV-10: Update on an Emerging Melanoma Therapy Wednesday May 22, 2013 An article appearing in the May 2013 edition of Practical Dermatology(10:5:31-32) summarizes PV-10 clinical development with input from Sanjiv S. Agarwala, MD. Recent non-clinical data supporting the use of PV-10 with other chemotherapeutic agents and demonstrating that intralesional PV-10 induces a systemic immune response are also discussed. Additionally, Dr. Agarwala discusses the suitability of IL PV-10 for use in a dermatology office setting. The article is available on the Practical Dermatology website at http://e-ditionsbyfry.com/Olive/ODE/PDM/Default.aspx?href=PDM%2F2013%2F05%2F01&pageno=31&view=document.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next